BridgeMD
IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)
EU CTIS ID: 2025-524834-24-00
What this study is testing
To evaluate the safety of IL-1β in a pilot series of pancreatic transplant patients.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients admitted to Nantes University Hospital for a pancreatic transplant (alone or combined with a kidney transplant)
- Pancreatic transplant priority level: 1, 2 or 3.
- Age ≥ 18 years
- Affiliated with the social security system
- Written consent to participate in the study
- Contraceptive measures and negative pregnancy test
You likely can't join if
- Patients under guardianship/curatorship
- Patients under judicial protection
- Pregnant or breastfeeding women
- Positive tuberculin Quantiferon test in the last 12 months.
- Hepatitis B viral replication in the last 12 months
- History of known hypersensitivity to Anakinra or any of the excipients or to proteins derived from E. coli
See the full eligibility criteria
- Patients admitted to Nantes University Hospital for a pancreatic transplant (alone or combined with a kidney transplant)
- Pancreatic transplant priority level: 1, 2 or 3.
- Age ≥ 18 years
- Affiliated with the social security system
- Written consent to participate in the study
- Contraceptive measures and negative pregnancy test
- Patients under guardianship/curatorship
- Patients under judicial protection
- Pregnant or breastfeeding women
- Positive tuberculin Quantiferon test in the last 12 months.
- Hepatitis B viral replication in the last 12 months
- History of known hypersensitivity to Anakinra or any of the excipients or to proteins derived from E. coli
- Neutropenia < 1500/mm3 prior to transplantation (current assessment)
- Patient unable to understand and speak French
- Patient participating in another interventional study (excluding RIRCM)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.